Durvalumab
- Generic Name
- Durvalumab
- Brand Names
- Imfinzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1428935-60-7
- Unique Ingredient Identifier
- 28X28X9OKV
- Background
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote normal immune responses that attack tum...
- Indication
Durvalumab is indicated for the treatment of adults with the following conditions:
- Associated Conditions
- Extensive-stage Small Cell Lung Cancer (SCLC), Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer, Metastatic Non-Small Cell Lung Cancer, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Stage III Non-small Cell Lung Cancer, Unresectable, locally advanced PD-L1 positive Lung Cancer Non-Small Cell Cancer (NSCLC)
- Associated Therapies
- First Line Chemotherapy
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 50
- Registration Number
- NCT06634199
- Locations
- 🇪🇸
Complejo Hospitalario Universitario Del Ferrol, Ferrol, A Coruña, Spain
🇪🇸ICO Badalona, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospitalario Universitario A Coruña, A Coruña, La Coruña, Spain
A Phase 1b Study of TTF in Combination With Durvalumab and GemCis in BTC.
- Conditions
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 60
- Registration Number
- NCT06611345
- Locations
- 🇨🇳
Anhui Provincial Hospital, He Fei, China
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-09-23
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 43
- Registration Number
- NCT06608940
- Locations
- 🇺🇸
Case Comprehensive Cancer Center Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT06606847
- Locations
- 🇷🇺
Research Site, Ufa, Russian Federation
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 33
- Registration Number
- NCT06591650
- Locations
- 🇨🇳
Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
- Conditions
- Interventions
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-11-15
- Target Recruit Count
- 25
- Registration Number
- NCT06564623
- Locations
- 🇺🇸
SKCCC Johns Hopkins Medical Institution, Baltimore, Maryland, United States
CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06548412
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Chemoimmunotherapy Combined with Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 15
- Registration Number
- NCT06546969
- Locations
- 🇺🇸
Maryland Proton Treatment Center, Baltimore, Maryland, United States
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas with Child-Pugh-B Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2024-07-29
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 32
- Registration Number
- NCT06526104
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 50
- Registration Number
- NCT06508216
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.